Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb 5:2021:6611897.
doi: 10.1155/2021/6611897. eCollection 2021.

The Effect of Cannabis on the Clinical and Cytokine Profiles in Patients with Multiple Sclerosis

Wessam Mustafa  1 , Nadia Elgendy  2 , Samer Salama  1 , Mohamed Jawad  1 , Khaled Eltoukhy  1
Affiliations

The Effect of Cannabis on the Clinical and Cytokine Profiles in Patients with Multiple Sclerosis

Wessam Mustafa et al. Mult Scler Int. .

Abstract

Background: Multiple studies have reported that cannabis administration in multiple sclerosis patients is associated with decreased symptom severity. This study was conducted to evaluate the prevalence of cannabis abuse in multiple sclerosis cases and to evaluate the effect of cannabis on serum cytokines in such cases. Patients and Methods. A total of 150 multiple sclerosis cases along with 150 healthy controls were included during the study period. All cases were subjected to history taking, neurological examination, and routine investigations. Cases were asked about cannabis intake which was confirmed by a urine test. Serum cytokines including IL-1, IL-2, IL-4, IL-10, IL-12, IL-17, IL-22, IFN-γ, IFN-β1, and TNF-α were ordered for all cases and controls.

Results: Twenty-eight cases were cannabis abusers (MS/cannabis group, 18.67%). The remaining 122 cases represented the MS group. There was no significant difference between the three groups regarding age, disease duration, or MS type. Male gender was more predominant in the MS/cannabis group, and the number of relapses was significantly lower in the same group. Fifteen cases (53.6%) reported that their symptoms were improved by cannabis. Proinflammatory cytokines were significantly elevated in the MS group compared to the MS/cannabis and control groups. Additionally, anti-inflammatory cytokines had significantly lower values in the MS group compared to the MS/cannabis and control groups. Most clinical symptoms were significantly improved in the MS/cannabis group compared to the MS group apart from sexual dysfunction, bladder symptoms, and visual disturbances. Mild side effects of cannabis were also reported.

Conclusion: Cannabis may have a positive impact on the cytokine and clinical profiles in cases with multiple sclerosis.

PubMed Disclaimer

Conflict of interest statement

All authors declare that they have no conflict of interest.

References

    1. Gupta S., Fellows K., Weinstock-Guttman B., Hagemeier J., Zivadinov R., Ramanathan M. Marijuana use by patients with multiple sclerosis. International journal of MS care. 2019;21(2):57–62. doi: 10.7224/1537-2073.2017-112. - DOI - PMC - PubMed
    1. Broadley S. A., Barnett M. H., Boggild M., et al. Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective part 3 treatment practicalities and recommendations. Journal of Clinical Neuroscience. 2014;21(11):1857–1865. doi: 10.1016/j.jocn.2014.01.017. - DOI - PubMed
    1. Broadley S. A., Barnett M. H., Boggild M., et al. Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective part 2 new and emerging therapies and their efficacy. Journal of Clinical Neuroscience. 2014;21(11):1847–1856. doi: 10.1016/j.jocn.2014.01.018. - DOI - PubMed
    1. Compston A., Coles A. Multiple sclerosis. The Lancet. 2008;372(9648):1502–1517. doi: 10.1016/S0140-6736(08)61620-7. - DOI - PubMed
    1. Zajicek J., Fox P., Sanders H., et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. The Lancet. 2003;362(9395):1517–1526. doi: 10.1016/S0140-6736(03)14738-1. - DOI - PubMed

LinkOut - more resources